Defencath-Taurolidine And Heparin
Defencath is a catheter lock solution used in adult dialysis patients with central venous catheters. It helps prevent bloodstream infections by combining antimicrobial and anti-clotting effects.
Augtyro-Repotrectinib
Augtyro is an oral treatment for ROS1-positive non-small cell lung cancer and NTRK fusion–positive tumors. It blocks key cancer-driving proteins to help slow tumor growth, especially in patients who’ve tried other therapies.
Truqap-CapIVasertib
Truqap is used with fulvestrant to treat certain advanced breast cancers with specific genetic mutations. It works by blocking the AKT pathway, which helps control tumor cell survival and growth.
Ogsiveo-Nirogacestat
Ogsiveo is an oral therapy for adults with desmoid tumors that are actively progressing. It targets a protein involved in tumor formation, helping reduce tumor size and manage symptoms.
Zevtera-Ceftobiprole Medocaril Sodium
Zevtera is an advanced-generation cephalosporin antibiotic for treating Staphylococcus aureus bacteremia, including right-sided endocarditis, skin infections, and pneumonia in both adults and children. It works by blocking bacterial cell wall synthesis and remains active against MRSA and resistant strains.
Lumisight-Pegulicianine
Lumisight is an IV fluorescent imaging agent used during lumpectomy to highlight residual breast cancer tissue inside the surgical cavity. This real-time tool helps surgeons ensure more complete tumor removal and aims to lower the need for additional surgery.
Ryzneuta-Efbemalenograstim Alfa-Vuxw
Ryzneuta is an injection that supports white blood cell production in cancer patients undergoing chemotherapy. It helps lower the risk of infection-related complications by boosting the immune system.
Livdelzi-Seladelpar
Livdelzi is used to treat primary biliary cholangitis (PBC). The purpose of Livdelzi is to efficiently target PPARδ, a peroxisome proliferator-activated receptor delta that inhibits the formation of bile acids.
Niktimvo-Axatilimab-Csfr
Niktimvo is an IV antibody treatment for adults and children (≥ 40 kg) with chronic graft‑versus‑host disease whose condition worsened despite at least two prior therapies. It works by blocking CSF‑1R to calm overactive immune cells and reduce symptoms.
Lazcluze-Lazertinib
Lazcluze (lazertinib) is an oral targeted therapy used with amivantamab for adults with advanced EGFR-mutated non‑small cell lung cancer. This regimen blocks mutant EGFR to delay disease progression, extending median progression-free survival to about 23.7 months.
